Revance Therapeutics, Inc.   Report issue

Contributed to NME For profit Phase 2 Phase 3
Founded: Newark CA United States (1999)
Status: No NME R&D (1999)

Organization Overview

First Clinical Trial
2008
NCT00888914
First Marketed Drug
2022
daxibotulinumtoxinA (Daxxify)
First NDA Approval
2022
daxibotulinumtoxinA (Daxxify)
Last Known Activity
2022

Timeline

NOW
  • Now

Alternative names

Revance Therapeutics, Inc. | REVANCE THERAPEUTICS, INC.

Active Ingredients

Marketed Drugs (1)

daxibotulinumtoxinA (Daxxify) (2022 NDA)

Drugs in Phase 3 Trials (2)

daxibotulinumtoxinA (Daxxify) (8 trials)

rimabotulinumtoxinB (Myobloc) (18 trials)

Drugs in Phase 2 Trials (1)

onabotulinumtoxinA (Botox) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Dystonia (Phase 3)

Dystonic Disorders (Phase 3)

Facies (Phase 2)

Fasciitis (Phase 2)

Fasciitis, Plantar (Phase 2)

Hyperhidrosis (Phase 2)

Muscle Spasticity (Phase 2)

Torticollis (Phase 3)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 27
  • # of Trial APIs: 3